Riverwater Partners LLC grew its position in Haemonetics Co. (NYSE:HAE - Free Report) by 12.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 50,379 shares of the medical instruments supplier's stock after purchasing an additional 5,538 shares during the period. Haemonetics makes up approximately 1.9% of Riverwater Partners LLC's investment portfolio, making the stock its 8th largest holding. Riverwater Partners LLC owned 0.10% of Haemonetics worth $3,934,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently modified their holdings of the company. Cerity Partners LLC increased its stake in Haemonetics by 31.1% in the 3rd quarter. Cerity Partners LLC now owns 8,855 shares of the medical instruments supplier's stock valued at $712,000 after buying an additional 2,102 shares during the last quarter. FMR LLC increased its position in shares of Haemonetics by 206.3% in the third quarter. FMR LLC now owns 774,529 shares of the medical instruments supplier's stock valued at $62,257,000 after acquiring an additional 521,640 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in Haemonetics by 174.5% during the third quarter. BNP Paribas Financial Markets now owns 16,949 shares of the medical instruments supplier's stock worth $1,362,000 after acquiring an additional 10,774 shares in the last quarter. Captrust Financial Advisors boosted its position in Haemonetics by 30.1% during the third quarter. Captrust Financial Advisors now owns 4,248 shares of the medical instruments supplier's stock valued at $341,000 after purchasing an additional 982 shares during the last quarter. Finally, Janus Henderson Group PLC grew its stake in Haemonetics by 19.0% in the third quarter. Janus Henderson Group PLC now owns 46,516 shares of the medical instruments supplier's stock valued at $3,735,000 after purchasing an additional 7,417 shares in the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
HAE has been the subject of a number of recent analyst reports. Barrington Research cut their price target on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. Bank of America lowered Haemonetics from a "neutral" rating to an "underperform" rating and dropped their price objective for the company from $95.00 to $68.00 in a research note on Friday, February 7th. JMP Securities reduced their target price on Haemonetics from $125.00 to $100.00 and set a "market outperform" rating for the company in a research note on Friday, February 7th. StockNews.com cut Haemonetics from a "buy" rating to a "hold" rating in a research note on Saturday, February 15th. Finally, Raymond James reiterated a "strong-buy" rating and issued a $115.00 price objective (down from $120.00) on shares of Haemonetics in a report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Haemonetics has a consensus rating of "Moderate Buy" and an average target price of $101.22.
View Our Latest Analysis on HAE
Haemonetics Price Performance
Shares of HAE stock traded down $2.89 during trading hours on Thursday, reaching $58.14. The company's stock had a trading volume of 289,889 shares, compared to its average volume of 682,310. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. Haemonetics Co. has a fifty-two week low of $55.30 and a fifty-two week high of $97.97. The company has a market capitalization of $2.92 billion, a price-to-earnings ratio of 22.85, a PEG ratio of 1.11 and a beta of 0.41. The firm's 50 day simple moving average is $63.92 and its 200-day simple moving average is $73.67.
Haemonetics (NYSE:HAE - Get Free Report) last issued its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. Sell-side analysts forecast that Haemonetics Co. will post 4.55 earnings per share for the current year.
Haemonetics Company Profile
(
Free Report)
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.
See Also
Before you consider Haemonetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.
While Haemonetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
